Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

    Results show prolonged courses of stable disease and excellent
    tolerability and indicate potential for use as combination treatment for
    cancer

QUEBEC CITY, Sept. 21 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer. Under the supervision of lead investigator, Daniel D. Von Hoff, MD, Senior Investigator and Physician in Chief at the Translational Genomics Research Institute in Scottsdale, Arizona, this open-label, dose-escalation, multi-center, intermittent treatment Phase 1 trial was conducted at 2 clinical sites in Scottsdale: the Mayo Clinic with principal investigator Donald W. Northfelt, MD, and at Premiere Oncology with principal investigator David Mendelson, MD.

Results

The study was performed in two parts and included 42 patients overall. In Part I, 22 patients were studied on doses ranging from 13 to 800 mg/week. In Part II, the weekly dose was split into 3 doses taken 8 hours apart, and ultimately, 20 patients received doses from 120 to 600 mg/week. Stable disease with time to failure ranging from 20 to 60+ weeks was achieved in 12 patients with various cancer types, including melanoma and cancers of the colon/rectum, lung, pancreas, prostate, tongue, trachea and thyroid. In several of these patients, the duration of stabilization exceeded the duration of disease control on previous treatment regimens. Except for a dose-limiting gastrointestinal reaction in a patient with pre-exis
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... on the status of the Company,s Series A ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 21 shares of Series A Preferred Stock and ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACTâ„¢, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... May 26, 2015   Intrexon Corporation (NYSE: ... Gregory Frost , Ph.D., Senior Vice President and Head ... Global Healthcare Conference on Wednesday, June 3 rd , at ... New York City . About Intrexon ... Powering the Bioindustrial Revolution with Better DNA ™ to ...
(Date:5/26/2015)... ORANGEBURG, N.Y. , May 26, 2015 /PRNewswire/ ... products and solutions, today announced that Oakwood Healthcare ... been selected as the winning entry in ... recognizing industry professionals who display excellence in building ... services (ES) teams in healthcare facilities.  ...
Breaking Biology Technology:RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... Virginia Key, Fla. Climate models have long predicted ... precipitation events. A new study conducted at the University ... the first observational evidence to confirm the link between ... One of the most serious challenges humanity will face ...
... DIEGO, Aug. 7 SGX Pharmaceuticals,(Nasdaq: SGXP ) today ... June 30, 2008. For the three months ended June 30, ... loss of $7.2 million. For,the six months ended June 30, ... million. The revenue in the six month period includes $10.8,million ...
... (Nasdaq: ISTA ), today reported financial results for the ... $17.8 million for the,quarter ended June 30, 2008, a 31% ... the second quarter ended June 30, 2008, was $8.5 million,(or ... $8.7 million (or $0.32,per share) for the same period in ...
Cached Biology Technology:Climate change: When it rains it (really) pours 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 2SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 3SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 4SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 5SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 6SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 7SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 8SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008 9ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 2ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 3ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 4ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 5ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 6ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 7
(Date:5/7/2015)... 2015 Fingerprint Cards (FPC) ... FPC1035, FPC,s smallest touch fingerprint sensors to date.  ... for integration on the backside of the phone, ... possibilities to integrate touch fingerprint sensors in the ... possibilities for module manufacturers to customize the look ...
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... study that looked at consumers who buy locally ... community-supported agriculture programs found the venues largely attract ... findings present a need for broadening local food ... payment plans and strategic efforts that make fresh ...
... are linked to one of the most lethal forms of ... of the genes found in the study are frequently altered ... of tumors. The findings appear in the Oct. 28, 2012, ... was led by researchers from the National Human Genome Research ...
... SAN FRANCISCO, CAOctober 28, 2012 Scientists at the Gladstone ... discovered how modifying a gene halts the toxic buildup ... point to a potential new tactic for treating a ... or Lou Gehrig,s disease)a fatal disease for which there ...
Cached Biology News:Greater effort needed to move local, fresh foods beyond 'privileged' consumers 2NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 2NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 3NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 4Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrig's disease 2Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrig's disease 3
Selective media for Salmonella...
... can be used as a fully functional, ... Software provides the means to record and ... These data can then be copied and ... Microsoft Excel or Lotus 123, or into ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Yeast Oligo Microarray Kit (V2), 2 ... simultaneously characterize expression of many thousands ... activity during important biological processes. Each ... 6,256 known ORFs from the S288C ...
Biology Products: